Literature DB >> 20458569

Severe osteoporosis treated with teriparatide in a patient affected by recessive epidermolysis bullosa dystrophica.

L Moretti1, A Notarnicola, A Panella, L Garofalo, R Garofalo, A Santamato, B Moretti.   

Abstract

In this work, we describe the clinical and instrumental results of our experience, the first reported in the literature, of the administration of teriparatide to treat severe osteoporosis secondary to epidermolysis bullosa. Already after 2 months of therapy, the patient, a 20-year-old affected by a recessive form of epidermolysis bullosa dystrophica, had less pain and a functional recovery resulting in an improved autonomy; a satisfactory increase in the densitometric values was documented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20458569     DOI: 10.1007/s00198-010-1278-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  9 in total

1.  Osteoporosis in a patient with recessive dystrophic epidermolysis bullosa.

Authors:  M Kawaguchi; Y Mitsuhashi; S Kondo
Journal:  Br J Dermatol       Date:  1999-11       Impact factor: 9.302

2.  Bone mineralization in children with epidermolysis bullosa.

Authors:  M S Fewtrell; J Allgrove; I Gordon; C Brain; D Atherton; J Harper; J E Mellerio; A E Martinez
Journal:  Br J Dermatol       Date:  2006-05       Impact factor: 9.302

3.  GB3 monoclonal antibody for the diagnosis of junctional epidermolysis bullosa: results of a multicenter study.

Authors:  O M Schofield; J D Fine; P Verrando; A H Heagerty; J P Ortonne; R A Eady
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

4.  Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005.

Authors:  Jemima E Mellerio; Madeline Weiner; Jacqueline E Denyer; Elizabeth I Pillay; Anne W Lucky; Anna Bruckner; Francis Palisson
Journal:  Int J Dermatol       Date:  2007-08       Impact factor: 2.736

5.  Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid.

Authors:  Marissa J Perman; Anne W Lucky; James E Heubi; Richard G Azizkhan
Journal:  Arch Dermatol       Date:  2009-01

6.  Maxillary alveolar process fracture complicating intubation in a patient with epidermolysis bullosa.

Authors:  M George; A E Martinez; J E Mellerio; R Nandi
Journal:  Paediatr Anaesth       Date:  2009-07       Impact factor: 2.556

7.  Prognostic implications of determining 180 kDa bullous pemphigoid antigen (BPAG2) gene/protein pathology in neonatal junctional epidermolysis bullosa.

Authors:  J E Mellerio; J E Denyer; D J Atherton; R A Eady; J A McGrath
Journal:  Br J Dermatol       Date:  1998-04       Impact factor: 9.302

8.  News from the first regional symposium on hereditary epidermolysis bullosa (Mediterranean - Central and Eastern Europe).

Authors:  Jasna Lipozencić
Journal:  Acta Dermatovenerol Croat       Date:  2009       Impact factor: 1.256

Review 9.  Osteoporosis: a review.

Authors:  Julie T Lin; Joseph M Lane
Journal:  Clin Orthop Relat Res       Date:  2004-08       Impact factor: 4.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.